Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 45-49

  Jin, Cao ^a   Lu, Lin ^a,b   Zhang, Rui Yan ^a   Zhang, Qi ^a   Ding, Feng Hua ^a   Chen, Qiu Jing ^b   Shen, Wei Feng ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adhesion molecule; Diffuse coronary artery disease; Glycated albumin; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA GLUCOSIDASE INHIBITOR; AMLODIPINE; ATORVASTATIN; C REACTIVE PROTEIN; ENALAPRIL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOSINOPRIL; GLYCOSYLATED ALBUMIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOSARTAN; METFORMIN; PENTOPRIL; SIMVASTATIN; SULFONYLUREA DERIVATIVE; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69849097164     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.003     Document Type: Article

References (38)

1. Johansen O.E., and Birkeland K.I. Preventing macrovascular disease in patients with type 2 diabetes mellitus. Am J Cardiovasc Drugs 3 (2003) 283-297
2. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics a postmortem study. Arterioscler Thromb Vasc Biol 24 (2004) 1266-1271
3. Natali A., Vichi S., Landi P., Severi S., L'Abbate A., and Ferrannini E. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia 43 (2000) 632-641
4. Takaishi H., Taniguchi T., Fujioka Y., Ishikawa Y., and Yokoyama M. Impact of increasing diabetes on coronary artery disease in the past decade. J Atheroscler Thromb 11 (2004) 271-277
5. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
6. Cohen M.P., Ziyadeh F.N., and Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 147 (2006) 211-219
7. Pu L.J., Lu L., Shen W.F., et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 71 (2007) 1067-1073
8. Higai K., Shimamura A., and Matsumoto K. Amadori-modified glycated albumin predominantly induces E-selectin expression on human vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 367 (2006) 137-143
9. Basta G., Lazzerini G., Del Turco S., Ratto G.M., Schmidt A.M., and De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced end products. Arterioscler Thromb Vasc Biol 25 (2005) 1401-1407
10. Yonekura H., Yamamoto Y., Sakurai S., Watanabe T., and Yamamoto H. Roles of receptor for advanced glycation end products in diabetes-induced vascular injury. J Pharmacol Sci 97 (2005) 305-311
11. Price C.L., and Knight S.C. Advanced glycation: a novel outlook on atherosclerosis. Curr Pharm Des 13 (2007) 3681-3687
12. Clynes R., Moser B., Yan S.F., Ramasamy R., Herold K., and Schmidt A.M. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 7 (2007) 743-751
13. Sun L., Ishida T., Yasuda T., et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 82 (2009) 371-381
14. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 (2003) 1097-1099
15. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 (2005) 2716-2721
16. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32 Suppl 1 (2009) S13-61
17. Klem I., Heitner J.F., Shah D.J., et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 47 (2006) 1630-1638
18. Ledru F., Ducimetière P., Battaglia S., et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol 37 (2001) 1543-1550
19. Di Sciascio G., Patti G., Nasso G., Manzoli A., D'Ambrosio A., and Abbate A. Early and long-term results of stenting of diffuse coronary artery disease. Am J Cardiol 86 (2000) 1166-1170
20. Cohen M.P., Shea E., Chen S., and Shearman C.W. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 141 (2003) 242-249
21. Cohen M.P. Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys 419 (2003) 25-30
22. Desfaits A.C., Serri O., and Renier G. Glycazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin. Diabetes Obes Metab 1 (1999) 113-120
23. Ichiki T., Funakoshi Y., Ito K., and Takeshita A. Expression of monocyte chemoattractant protein-1 by nonenzymatically glycated albumin (Amadori adducts) in vascular smooth muscle cells. Biochem Biophys Res Commun 269 (2000) 666-670
24. Hattori Y., Suzuki M., Hattori S., and Kasai K. Vascular smooth muscle cell activation by glycated albumin (amadori adducts). Hypertension 39 (2002) 22-28
25. Hattori Y., Banba N., Gross S.S., and Kasai K. Glycated serum albumin-induced nitric oxide production in vascular smooth muscle cells by nuclear factor kappaB-dependent transcriptionl activation of inducible nitric oxide synthase. Biochem Biophys Res Commun 1 (1999) 128-132
26. Bourdon E., Loreau N., and Blache D. Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 13 (1999) 233-244
27. Singh N.R., Rondeau P., Hoareau L., and Bourdon E. Identification of preferential protein targets for carbonylation in human mature adipocytes treated with native or glycated albumin. Free Radic Res 41 (2007) 1078-1088
28. Tayebjee M.H., Lip G.Y.P., and MacFadyen R.J. What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus?. Diabet Med 22 (2005) 1628-1635
29. Wohlfarth V., Drumm K., Mildenberger S., Freudinger R., and Gekle M. Protein uptake disturbs collagen homeostasis in proximal tubule-derived cells. Kidney Int Suppl 84 (2003) S103-109
30. Koga M., Otsuki M., Matsumoto S., Saito H., Mukai M., and Kasayama S. Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chim Acta 378 (2007) 48-52
31. Miyashita Y., Nishimura R., Morimoto A., Matsudaira T., Sano H., and Tajima N. Glycated albumin is low in obese, type 2 diabetic patients. Diabetes Res Clin Pract 78 (2007) 51-55
32. Ravipati G., Aronow W.S., Ahn C., Sujata K., Saulle L.N., and Weiss M.B. Association of hemoglobin A(1c) level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 97 (2006) 968-969
33. Schram M.T., Schalkwijk C.G., Bootsma A.H., Fuller J.H., Chaturvedi N., and Stehouwer C.D. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 46 (2005) 232-237
34. Yamada S., Inaba M., Shidara K., et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 83 (2008) 516-519
35. Kumeda Y., Inaba M., Shoji S., et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol 69 (2008) 556-561
36. Tan K.C., Chow W.S., Tam S., Bucala R., and Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27 (2004) 223-228
37. Yoshida T., Yamagishi S., Nakamura K., et al. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 580 (2006) 2788-2796
38. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18 (1998) 1386-1392